Elixxer Ltd (ELXR) - Net Assets
Based on the latest financial reports, Elixxer Ltd (ELXR) has net assets worth CA$-15.05 Million CAD (≈ $-10.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$2.17 Million ≈ $1.57 Million USD) and total liabilities (CA$17.22 Million ≈ $12.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ELXR tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-15.05 Million |
| % of Total Assets | -692.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -375.15% |
| 10-Year Change | N/A |
| Growth Volatility | 473.78 |
Elixxer Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Elixxer Ltd's net assets have evolved over time, based on quarterly financial data. See ELXR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Elixxer Ltd (2017–2024)
The table below shows the annual net assets of Elixxer Ltd from 2017 to 2024. For live valuation and market cap data, see Elixxer Ltd (ELXR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-13.09 Million ≈ $-9.47 Million |
-36.38% |
| 2023-12-31 | CA$-9.60 Million ≈ $-6.94 Million |
-71.90% |
| 2022-12-31 | CA$-5.58 Million ≈ $-4.04 Million |
-166.64% |
| 2021-12-31 | CA$8.38 Million ≈ $6.06 Million |
+76.12% |
| 2020-12-31 | CA$4.76 Million ≈ $3.44 Million |
-73.08% |
| 2018-12-31 | CA$17.67 Million ≈ $12.79 Million |
+1021.20% |
| 2017-12-31 | CA$1.58 Million ≈ $1.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Elixxer Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7497077900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$74.88 Million | % |
| Total Equity | CA$-13.09 Million | 100.00% |
Elixxer Ltd Competitors by Market Cap
The table below lists competitors of Elixxer Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arecor Therapeutics PLC
LSE:AREC
|
$287.12K |
|
East Star Resources PLC
LSE:EST
|
$287.76K |
|
Sino-German United AG
F:SGU
|
$288.00K |
|
Global PVQ SE
HM:QCE
|
$288.63K |
|
Altair Resources Inc
V:AVX
|
$286.33K |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
$286.13K |
|
Annum Bhd
KLSE:5082
|
$285.59K |
|
Provexis plc
LSE:PXS
|
$285.43K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elixxer Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -9,600,419 to -13,092,854, a change of -3,492,435.
- Net loss of 3,466,845 reduced equity.
- Other factors decreased equity by 25,590.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-3.47 Million | -26.48% |
| Other Changes | CA$-25.59K | -0.2% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Elixxer Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$0.01 | CA$0.04 | x |
| 2018-12-31 | CA$0.05 | CA$0.04 | x |
| 2020-12-31 | CA$0.01 | CA$0.04 | x |
| 2021-12-31 | CA$0.75 | CA$0.04 | x |
| 2022-12-31 | CA$-0.49 | CA$0.04 | x |
| 2023-12-31 | CA$-0.85 | CA$0.04 | x |
| 2024-12-31 | CA$-1.15 | CA$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elixxer Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-94.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -320.21% | 0.00% | 0.00x | 1.74x | CA$-5.21 Million |
| 2018 | -93.53% | -9580.17% | 0.01x | 1.17x | CA$-18.30 Million |
| 2020 | -205.60% | -60124.52% | 0.00x | 4.37x | CA$-10.26 Million |
| 2021 | -43.70% | -8636.02% | 0.00x | 2.01x | CA$-4.50 Million |
| 2022 | 0.00% | -17256.80% | 0.02x | 0.00x | CA$-13.61 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-3.05 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-2.16 Million |
Industry Comparison
This section compares Elixxer Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $713,486,636
- Average return on equity (ROE) among peers: -56.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elixxer Ltd (ELXR) | CA$-15.05 Million | -320.21% | N/A | $287.08K |
| Aurora Cannabis Inc (ACB) | $1.69 Million | -10.52% | 0.00x | $171.89 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $12.28 Million |
| Avant Brands Inc (AVNT) | $32.85 Million | -68.65% | 0.81x | $6.98 Million |
| Bausch Health Companies Inc (BHC) | $5.94 Billion | 40.44% | 5.31x | $1.87 Billion |
| CanadaBis Capital Inc (CANB) | $2.63 Million | 23.10% | 4.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $18.41 Million | -56.20% | 0.05x | $297.74 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $76.24 Million | -32.43% | 0.15x | $118.76 Million |
About Elixxer Ltd
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Mon… Read more